Kenneth C. Frazier, chairman and chief executive officer (CEO) of Merck & Co., Inc., has been elected chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Also, PhRMA’s president and CEO John J. Castellani announced that he will be retiring effective January 1, 2016.
Frazier formerly held the position of chairman-elect of PhRMA and succeeds Ian C. Read, chairman and CEO of Pfizer, Inc. Also elected were George A. Scangos, PhD., CEO of Biogen, as chairman-elect of the PhRMA board of directors and Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson, as Board treasurer.
Before becoming chairman and CEO of Merck in 2011, Frazier served as president of Merck with responsibility for the company’s three major divisions: Global Human Health, Merck’s sales and marketing division for pharmaceutical and vaccine products; Merck Manufacturing, the company’s manufacturing and supply division; and Merck Research Laboratories, Merck’s research organization. He previously served as president of Merck Global Human Health from 2007 to 2010 and as general counsel, overseeing Merck’s legal and public affairs functions and The Merck Foundation from 1999 to 2007.
Dr. Scangos was appointed CEO of Biogen in June 2010. He joined the company from Exelixis, Inc., where he served as president and CEO from October 1996. From 1987 to 1996, Scangos held various positions at Bayer, Inc., including senior vice president of research and development, and president of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering, and quality assurance of Bayer’s recombinant products.
Duato became worldwide chairman, pharmaceuticals, Johnson & Johnson, in January 2011. Prior to his current role, Duato held the positions of company group chairman, the Americas, and company group chairman, Ortho Clinical Diagnostics, Inc. Duato joined Johnson & Johnson in 1989 in Janssen-Cilag Spain and later became managing director of Janssen-Cilag Italy. He then led Ortho Biotech Europe before relocating to the United States in 2002 as vice president for the Ortho Biotech Oncology Franchise. He was named president, Ortho Biotech Products, L.P. in 2005.
Castellani will step down as president and CEO of PhRMA after leading the association since September 2010. The search for Castellani’s successor has begun and will be led by the PhRMA Board's Governance and Compensation Committee.